NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
    4.
    发明公开
    NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE 失效
    USED​​ AS法呢基蛋白质三环哌啶衍生物抑制剂转移酶

    公开(公告)号:EP0931078A1

    公开(公告)日:1999-07-28

    申请号:EP97941477.0

    申请日:1997-09-11

    IPC分类号: A61K31 A61P35 C07D401 C07D405 C07F9

    摘要: Novel tricyclic compounds of formula (1.0) or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c, and d represents N or NR9, wherein R9 is O-, -CH¿3? or -(CH2)nCO2H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR?1 or CR2¿; or each of a, b, c and d is independently selected from CR?1 or CR2¿; each R1 and each R2 is independently selected from H, halo, -CR¿3?, -OR?10, -COR10, -SR10¿, -S(O)¿tR?11 (wherein t is 0, 1 or 2), -SCN, -N(R10)2, -NR?10R11, -NO¿2, -OC(O)R10, -CO2R10, -OCO¿2R?11, -CN, -NHC(O)R10, -NHSO¿2R?10, -CONHR10, -CONHCH¿2?CH2OH, -NR?10COOR11, -SR11C(O)OR11, -SR11N(R75)2¿; n is 0 (zero), 1, 2, 3, 4, 5 or 6; T is -CO-; -SO-; -SO¿2?-; or -CR?30R31¿-; Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR?40, -SR40, -CR40R42, -NR40R42¿, formulae (i), (ii), (iii), (iv), (v) and (vi). Pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel tricyclic compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.

    NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
    8.
    发明授权
    NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE 失效
    USED​​ AS法呢基蛋白质三环哌啶衍生物抑制剂转移酶

    公开(公告)号:EP0931078B1

    公开(公告)日:2006-11-15

    申请号:EP97941477.8

    申请日:1997-09-11

    摘要: Novel tricyclic compounds of formula (1.0) or a pharmaceutically acceptable salt or solvate thereof, wherein: one of a, b, c, and d represents N or NR9, wherein R9 is O-, -CH¿3? or -(CH2)nCO2H wherein n is 1 to 3, and the remaining a, b, c and d groups represent CR?1 or CR2¿; or each of a, b, c and d is independently selected from CR?1 or CR2¿; each R1 and each R2 is independently selected from H, halo, -CR¿3?, -OR?10, -COR10, -SR10¿, -S(O)¿tR?11 (wherein t is 0, 1 or 2), -SCN, -N(R10)2, -NR?10R11, -NO¿2, -OC(O)R10, -CO2R10, -OCO¿2R?11, -CN, -NHC(O)R10, -NHSO¿2R?10, -CONHR10, -CONHCH¿2?CH2OH, -NR?10COOR11, -SR11C(O)OR11, -SR11N(R75)2¿; n is 0 (zero), 1, 2, 3, 4, 5 or 6; T is -CO-; -SO-; -SO¿2?-; or -CR?30R31¿-; Z represents alkyl, aryl, aralkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, -OR?40, -SR40, -CR40R42, -NR40R42¿, formulae (i), (ii), (iii), (iv), (v) and (vi). Pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel tricyclic compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human.